Publications by authors named "Kotaro Tokui"

Claim this Profile
T
TTF-1 expression is associated with survival in patients with non-squamous non-small cell lung cancer treated with immune checkpoint inhibitor therapy.
Nozomu Murayama, Minehiko Inomata, Daisuke Furukawa, Moe Hashizume, Naoki Takata, Kotaro Tokui

Mol Clin Oncol· February 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TGFβ1 and SMAD3 Expression Are Associated With Survival After the Immune Checkpoint Inhibitor Therapy for Small Cell Lung Cancer.
Zenta Seto, Minehiko Inomata, Akira Noguchi, Tomonobu Kado, Nozomu Murayama, Kotaro Tokui

Cancer Rep (Hoboken)· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter Retrospective Analysis of Pulmonary Sarcomatoid Carcinoma Clinically Diagnosed Using Small Biopsy Specimens.
Minehiko Inomata, Takeshi Tsuda, Tomomi Ichikawa, Masahiro Matsumoto, Isami Mizushima, Kotaro Tokui

Cancer Diagn Progn· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Case of EGFR-mutant Squamous Cell Lung Cancer Treated With Necitumumab Combination Therapy.
Minehiko Inomata, Daisuke Furukawa, Naoki Takata, Kotaro Tokui, Seisuke Okazawa

In Vivo· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of Chemoimmunotherapy in Small-cell Lung Cancer Patients With a Poor Performance Status or Higher Neutrophil/Lymphocyte Ratio.
Minehiko Inomata, Naoki Takata, Zenta Seto, Nozomu Murayama, Kotaro Tokui

In Vivo· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An observational study on the efficacy of targeted therapy for pulmonary sarcomatoid carcinoma.
Takeshi Tsuda, Tomomi Ichikawa, Masahiro Matsumoto, Isami Mizusihima, Kenji Azechi, Kotaro Tokui

Discov Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the efficacy of first‑/second‑generation EGFR‑tyrosine kinase inhibitors and osimertinib for EGFR‑mutant lung cancer with negative or low PD‑L1 expression.
Minehiko Inomata, Shuhei Minatoyama, Naoki Takata, Kana Hayashi, Takahiro Hirai, Kotaro Tokui

Mol Clin Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pure Red Cell Aplasia and Chromosomal Abnormality in a Patient With Lung Adenocarcinoma Receiving Immune Checkpoint Inhibitors: A Case Report.
Takahiro Hirai, Minehiko Inomata, Shuhei Minatoyama, Moe Hashizume, Naoki Takata, Kotaro Tokui

In Vivo· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune Checkpoint Inhibitor Therapy for Patients With Non-small Cell Lung Cancer Ineligible for Platinum Doublet Chemotherapy.
Minehiko Inomata, Shuhei Minatoyama, Naoki Takata, Kana Hayashi, Takahiro Hirai, Kotaro Tokui

Anticancer Res· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association Between the Severity of Immune-related Adverse Events and the Prognosis in Patients With Non-small Cell Lung Cancer Receiving Treatment With Immune Checkpoint Inhibitors.
Minehiko Inomata, Masahiro Matsumoto, Kana Hayashi, Zenta Seto, Takahiro Hirai, Kotaro Tokui

Anticancer Res· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peripheral CD4 memory T cells predict the efficacy of immune checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Minehiko Inomata, Masahiro Matsumoto, Naoki Takata, Kana Hayashi, Zenta Seto, Kotaro Tokui

Sci Rep· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of immune checkpoint inhibitor therapy in patients with pulmonary sarcomatoid carcinoma in clinical practice.
Minehiko Inomata, Takeshi Tsuda, Tomomi Ichikawa, Masahiro Matsumoto, Isami Mizushima, Kotaro Tokui

Thorac Cancer· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Associations of immune checkpoint inhibitor therapy efficacy with clinical parameters and tumor‑infiltrating CD68‑positive cell counts in patients with EGFR‑mutant non‑small cell lung cancer.
Takeshi Tsuda, Kensuke Suzuki, Minehiko Inomata, Kana Hayashi, Isami Mizushima, Kotaro Tokui

Mol Clin Oncol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Tumor PD-L1 Expression With Time on Treatment Using EGFR-TKIs in Patients With EGFR-Mutant Non-small Cell Lung Cancer.
Minehiko Inomata, Masahiro Matsumoto, Isami Mizushima, Zenta Seto, Kana Hayashi, Kotaro Tokui

Cancer Diagn Progn· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Irinotecan monotherapy as third- or further-line treatment for patients with small cell lung cancer.
Zenta Seto, Naoki Takata, Nozomu Murayama, Kotaro Tokui, Seisuke Okazawa

Tumori· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune Checkpoint Inhibitor for Non-small Cell Lung Cancer With Negative or Low Tumor PD-L1 Expression.
Minehiko Inomata, Naoki Takata, Isami Mizushima, Kenji Azechi, Kana Hayashi, Kotaro Tokui

Cancer Diagn Progn· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case Series of Pleomorphic Carcinoma of the Lung Treated With Immune Checkpoint Inhibitors.
Kana Hayashi, Kotaro Tokui, Minehiko Inomata, Kenji Azechi, Isami Mizushima

In Vivo· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationship between Patient Characteristics and the Timing of Provision of Explanation about DNAR to Patients with Advanced Lung Cancer.
Minehiko Inomata, Takahiro Hirai, Naoki Takata, Nozomu Murayama, Kana Hayashi, Kotaro Tokui

Intern Med· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Tumor PD-L1 Expression with the T790M Mutation and Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Receiving EGFR-TKI Therapy.
Minehiko Inomata, Kenji Azechi, Naoki Takata, Kana Hayashi, Kotaro Tokui

Diagnostics (Basel)· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Parameters for Predicting the Survival in Patients with Squamous and Non-squamous-cell NSCLC Receiving PD-1 Inhibitor Therapy.
Minehiko Inomata, Takahiro Hirai, Zenta Seto, Kotaro Tokui, Chihiro Taka

Pathol Oncol Res· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peripheral PD1-positive CD4 T-Lymphocyte Count Can Predict Progression-free Survival in Patients With Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor.
Minehiko Inomata, Tomonobu Kado, Seisuke Okazawa, Shingo Imanishi, Chihiro Taka, Kotaro Tokui

Anticancer Res· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SIRT1 and FOXO1 mRNA expression in PBMC correlates to physical activity in COPD patients.
Chihiro Taka, Ryuji Hayashi, Kazuki Shimokawa, Kotaro Tokui, Seisuke Okazawa

Int J Chron Obstruct Pulmon Dis· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daptomycin-induced Eosinophilic Pneumonia and a Review of the Published Literature.
Yoshitsugu Higashi, Shigeki Nakamura, Yasuhiro Tsuji, Chika Ogami, Kaoru Matsumoto, Kotaro Tokui

Intern Med· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[A Retrospective Study Analyzing the Clinical Course of Patients with Non-Small Cell Lung Cancer Receiving Local or Systemic Therapy after Post-Operative Recurrence].
Minehiko Inomata, Hiroaki Tanaka, Kazuki Shimokawa, Kotaro Tokui, Seisuke Okazawa

Gan To Kagaku Ryoho· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[A Case of Lung Adenocarcinoma Presenting with Leptomeningeal Carcinomatosis Successfully Treated with Afatinib after Erlotinib-Induced Hepatotoxicity].
Hiroaki Tanaka, Minehiko Inomata, Ryuji Hayashi, Kazuki Shimokawa, Kotaro Tokui

Gan To Kagaku Ryoho· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis